Mydecine Innovations Group (OTCPK:MYCO.F) - Cotización, noticias y análisis

Resumen de acción MYCO.F

Mydecine Innovations Group Inc, empresa de biotecnología, se dedica al desarrollo y comercialización de productos de psilocibina para el tratamiento de problemas de salud mental.

Acerca de la empresa

MYCO.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Recompensas

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares (CA$0)

Alta volatilidad del precio de la acción en los últimos 3 meses

Los beneficios han disminuido en 6.3% al año en los últimos 5 años.

Patrimonio neto negativo

+ 2 riesgos adicionales

Competidores de Mydecine Innovations Group Inc.

Stem Holdings

OTCPK:STMH

US$577.3k

Ampio Pharmaceuticals

OTCPK:AMPE

US$563.2k

InMed Pharmaceuticals

NasdaqCM:INM

US$1.8m

AmeriCann

OTCPK:ACAN

US$1.6m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Mydecine Innovations Group
Historical stock prices
Current Share Price	US$0.013
52 Week High	US$0.45
52 Week Low	US$0.0001
Beta	3.2
1 Month Change	-38.96%
3 Month Change	10.85%
1 Year Change	-97.09%
3 Year Change	-99.92%
5 Year Change	-99.97%
Change since IPO	-100.00%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	MYCO.F	US Pharmaceuticals	Mercado US
7D	12.6%	-1.4%	-3.2%
1Y	-97.1%	9.7%	19.3%

Rentabilidad vs. Industria: MYCO.F obtuvo unos resultados inferiores a los del sector US Pharmaceuticals , que el año pasado arrojó un rendimiento del -4.4%.

Rentabilidad vs. Mercado: MYCO.F obtuvo unos resultados inferiores a los del mercado US, que fue del 15.2% el año pasado.

Volatilidad de los precios

Is MYCO.F's price volatile compared to industry and market?
MYCO.F volatility
MYCO.F Average Weekly Movement	5,645.7%
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: MYCO.Fha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: MYCO.FLa volatilidad semanal ha pasado de 42% a 68% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2013	3	Josh Bartch	www.mydecine.com

Mydecine Innovations Group Inc, empresa de biotecnología, se dedica al desarrollo y comercialización de productos de psilocibina para el tratamiento de problemas de salud mental. La empresa se centra principalmente en el tratamiento para dejar de fumar. Sus principales productos candidatos a fármacos son MYCO-001, MYCO-002, MYCO003 y MYCO-004.

Resumen de fundamentos de Mydecine Innovations Group Inc.

¿Cómo se comparan los beneficios e ingresos de Mydecine Innovations Group con su capitalización de mercado?
Estadísticas fundamentales de MYCO.F
Capitalización bursátil	US$771.94k
Beneficios(TTM)	-US$13.14m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-0.1x

Ratio precio-beneficio (PE)

¿Está MYCO.F sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de MYCO.F
Ingresos	CA$0
Coste de los ingresos	CA$0
Beneficio bruto	CA$0
Otros gastos	CA$18.07m
Beneficios	-CA$18.07m

Últimos beneficios comunicados

Sep 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.29
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	-84.4%

¿Cómo se ha desempeñado MYCO.F a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción MYCO.F

Recompensas

Análisis de riesgos

Competidores de Mydecine Innovations Group Inc.

OTCPK:STMH

US$577.3k

OTCPK:AMPE

US$563.2k

NasdaqCM:INM

US$1.8m

OTCPK:ACAN

US$1.6m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Recent updates

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Mydecine Innovations Group Inc., Annual General Meeting, Apr 20, 2023

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Pangenomic Health Inc. (CNSX:NARA) completed the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F).

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 4.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Mydecine Innovations Group Inc. Announces Appointment of John Ross as Its Chief Financial Officer

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering.

Pangenomic Health Inc. (CNSX:NARA) signed an arm's length non binding Letter of Intent to acquire Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F) for CAD 4 million.

Mydecine Innovations Group Inc. Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces CFO Changes

Mydecine Innovations Group Inc. Announces Resignation of Directors

Mydecine Files Full Patent Application Covering Myco-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Mydecine Innovations Group Inc. Announces Board Changes

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 4 million.

Mydecine Innovations Group Inc. has completed a Composite Units Offering.

Mydecine Innovations Group Inc., Annual General Meeting, May 26, 2022

Mydecine Innovations Group Inc. Reports Positive Pre-IND Meeting with FDA for MYCO-001 Smoking Cessation Study

Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Mydecine Innovations Group Inc. to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic- Assisted Psychotherapy for Patients

Mydecine Innovations Group Inc. Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial

Mydecine Innovations Group Inc. Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Mydecine Innovations Group Inc. announced that it expects to receive CAD 5.5 million in funding

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Mydecine Innovations Group Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Mydecine Provides Business Update

Mydecine Innovations Group Expands Portfolio of Novel Molecules Filing New Patent for MDMA-Like Compounds

Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004

Mydecine Unveils Artificial Intelligence Drug Discovery Program

Mydecine Innovations Group Discovers over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms

Health Canada Approves Expansion of Mydecine's Cultivation Capabilities for Psilocybin Producing Mushrooms

Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms

Mydecine Innovations Group Announces Management Changes

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies Its Clinical and Commercial Supply Chain

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 15 million.

Mydecine Innovations Group Announces Management Changes

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors

Mydecine Innovations Group Announces the Filing of Seven Provisional Patent Applications with the United States Patent and Trademark Office

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials

Mydecine Innovations Group Launches Mindleap app

Mydecine Innovations Group Inc. Announces Appointment of Rakesh Jetly as Chief Medical Officer

Mydecine Innovations Group Inc. (CNSX:MYCO) completed the acquisition of NeuroPharm Inc.

NewLeaf Brands Inc. (CNSX:NLB) completed the acquisition of Mindleap Health.

Mydecine Innovations Group Inc. announced that it has received CAD 2.4 million in funding

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Mydecine Innovations Group Inc.

0.0x

-0.1x

Beneficios e Ingresos